Assessing hepatotoxicity in novel and standard short regimens for rifampicin-resistant tuberculosis: Insights from the TB-TRUST and TB-TRUST-plus trials
GastroenterologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
- Publicado em
- 4 set 2024
- Citações
- 10
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Assessing hepatotoxicity in novel and standard short regimens for rifampicin-resistant tuberculosis: Insights from the TB-TRUST and TB-TRUST-plus trials
Lingyun Song, Yilin Zhang, Feng Sun, Yuanbo Lan, Jie Tong, Shijia Ge, Zhen Feng, Rong Li, Hongying Yu, Yang Li et al.
Descritores MeSH
- Antitubercular Agents
- Liver Function Tests
- Rifampin
- Tuberculosis, Multidrug-Resistant
- Chemical and Drug Induced Liver Injury
- Diarylquinolines
- Levofloxacin
- Male
- Alanine Transaminase
- Female
Veja também
Estudos relacionados
- Hepatic Safety of Bedaquiline, Delamanid, and Pretomanid: A Systematic Review and Meta-analysis
- Chinese guideline for the chemotherapy of multidrug-resistant/rifampicin-resistant tuberculosis (2026 edition)
- A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis
- Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in China